转自：成都日报锦观 这串编码是医保领域的"万能钥匙"，在收费结算、医保报销、基金监管等各个环节都发挥着关键作用。 目前医保药品数据库里已收录上万条中药饮片编码，覆盖3000多种中药材，涵盖22类不同功效，真正实 现了"全国一码通用"，不仅提升了医保服务效率，为中医药的规范化、标准化发展打下了坚实的数据基 础，也让老百姓抓药报销少走了不少弯路。 新版"医保身份证"的"新"意藏在哪？ 据介绍，这次修订不搞"大改大动"，是在保留"中药饮片识别码、标准分类码、功效分类码、中药饮片 名称码"4大核心要素基础上，新增"道地药材标识码"和"中药饮片企业码"两个关键码段，填补"是否道 地、谁来生产"的信息空白，大幅提升透明度。新增道地药材标识码，如同给饮片贴了地理认证标签， 云南三七、四川川贝等道地品种一查便知；新增企业码实现生产责任精准锁定，厂家信息清晰可溯，既 倒逼企业压实主体责任，也为中药饮片集中采购落地筑牢根基。 国家医保局有关负责人表示，医保服务将更暖更贴心中药饮片的"医保身份证"升级背后，是医保管理的 不断精细化，更是对人民群众就医用药需求的贴心回应。下一步，国家医保局将持续完善中药饮片信息 数据库，组织相关企业 ...

Core Viewpoint - New Lotus is one of the largest suppliers of traditional Chinese medicine (TCM) herbal pieces in China, ranking second in the market with a 0.4% market share and a compound annual growth rate (CAGR) of 27% from 2022 to 2024 [2][3] Company Overview - New Lotus operates a dual-pillar strategy, focusing on both the core TCM market and modern consumer-oriented solutions, serving over 1,000 hospitals and large pharmacy chains while also tapping into retail market growth [2] - The company is expanding its global presence through herbal product exports and establishing localized operations in high-potential international markets [2] Market Potential - The TCM herbal pieces market is projected to reach RMB 306.7 billion in 2024, making it the fastest-growing segment in the pharmaceutical industry [3] - New Lotus offers over 770 types and 4,900 categories of herbal pieces, with significant contributions from toxic pieces like Ban Xia and common pieces like Chuan Bei Mu and Dang Gui [3] Financial Performance - Revenue figures for New Lotus are as follows: - 2022: RMB 780.4 million - 2023: RMB 1,145.6 million - 2024: RMB 1,249.4 million - First half of 2024: RMB 598.7 million - First half of 2025: RMB 633.5 million [4] - Profit figures for the same periods are: - 2022: RMB 77.4 million - 2023: RMB 104.0 million - 2024: RMB 89.1 million - First half of 2024: RMB 42.7 million - First half of 2025: RMB 51.2 million [4]

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Decoction Pieces Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with GF Securities (Hong Kong) and Agricultural Bank of China International as joint sponsors [1] Company Overview - Xinhehua is one of the largest suppliers of traditional Chinese medicine decoction pieces in China, ranking second in the market with a 0.4% market share as of 2024, according to Frost & Sullivan [4] - The company is the fastest-growing among the top five market participants, with a compound annual growth rate (CAGR) of 27% in revenue from 2022 to 2024 [4] Business Strategy - The company employs a dual-pillar strategy that balances its leadership in the core traditional Chinese medicine market with rapid response solutions for modern consumers [4] - Xinhehua serves over 1,000 hospitals and medical institutions, as well as large chain pharmacies, small pharmacies, clinics, and operators through offline channels [4] - The company aims to tap into global opportunities by exporting herbal products and establishing localized operations in high-potential international markets [4] Market Potential - The market for traditional Chinese medicine decoction pieces is projected to reach RMB 306.7 billion in 2024, making it the fastest-growing segment in the pharmaceutical industry [5] - Xinhehua's revenue comes from over 770 types and 4,900 categories of decoction pieces, with significant contributions from toxic decoction pieces such as Banxia and Jiangbanxia, as well as common decoction pieces like Chuanbeimu, Maidong, and Danggui [5] Financial Performance - Xinhehua's revenue for the years ending December 31 for 2022, 2023, and 2024, as well as for the six months ending June 30, 2024, and 2025, is as follows: - 2022: RMB 780 million - 2023: RMB 1.145 billion - 2024: RMB 1.249 billion - 2024 (six months): RMB 599 million - 2025 (six months): RMB 633 million [5][6] - The company's profits for the same periods are: - 2022: RMB 77.4 million - 2023: RMB 104.0 million - 2024: RMB 89.1 million - 2024 (six months): RMB 42.7 million - 2025 (six months): RMB 51.2 million [5][6]

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Co., Ltd. (referred to as "Xinhehua") has submitted an application for an IPO on the Hong Kong Stock Exchange, with Guangfa Securities (Hong Kong) and Agricultural Bank of China International as sponsors. The company aims to raise funds to expand its production capacity and explore overseas markets [1][10]. Group 1: Company Overview - Xinhehua specializes in the research, production, and sales of traditional Chinese medicine pieces, ranking second in China based on revenue from traditional Chinese medicine products in 2023 [2][3]. - The company has attempted to list on the A-share market multiple times but has not succeeded [2][10]. Group 2: Financial Performance - Xinhehua's revenue for the years 2022, 2023, and 2024 was 780.4 million RMB, 1.146 billion RMB, and 1.249 billion RMB, respectively, with net profits of 77.4 million RMB, 104.6 million RMB, and 89.1 million RMB [3][4]. - The gross profit margin has been declining, with total gross margins of 21.1%, 18.5%, and 17.1% for the years 2022, 2023, and 2024 [5][6]. Group 3: Product and Market Dynamics - A significant portion of Xinhehua's revenue comes from a limited range of products, with the top five products accounting for 26.5% of total annual revenue in 2024 [5]. - The gross profit margin for toxic traditional Chinese medicine pieces decreased from 29.7% in 2022 to 19.1% in 2024, while the margin for ordinary pieces fell from 19.6% to 16.7% during the same period [5][6]. Group 4: Future Plans and Use of Proceeds - The funds raised from the IPO will be used for expanding production capacity, upgrading digital production systems, enhancing sales and marketing activities, establishing overseas sales channels in Vietnam and Malaysia, and strategic investments and potential acquisitions [10].